Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in Net LoansChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Net Cash Flow (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Net Cash Flow for 12 consecutive years, with $460828.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 225.8% year-over-year to $460828.0, compared with a TTM value of $1.1 million through Dec 2025, up 412.22%, and an annual FY2025 reading of $442906.0, up 158.07% over the prior year.
  • Net Cash Flow was $460828.0 for Q4 2025 at Abvc Biopharma, up from -$274219.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $2.8 million in Q3 2021 and bottomed at -$3.5 million in Q2 2022.
  • Average Net Cash Flow over 5 years is -$304478.7, with a median of -$174473.0 recorded in 2023.
  • Peak annual rise in Net Cash Flow hit 1212.0% in 2021, while the deepest fall reached 7940.08% in 2021.
  • Year by year, Net Cash Flow stood at $2.2 million in 2021, then tumbled by 137.02% to -$797857.0 in 2022, then skyrocketed by 70.19% to -$237869.0 in 2023, then crashed by 54.0% to -$366312.0 in 2024, then surged by 225.8% to $460828.0 in 2025.
  • Business Quant data shows Net Cash Flow for ABVC at $460828.0 in Q4 2025, -$274219.0 in Q3 2025, and $1.0 million in Q2 2025.